CD44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor

References

• Dtzer K, Schlüter F, Koch FEV, et al. Integrin α2β1 represents a prognostic and predictive biomarker in primary ovarian cancer. Biomedicines. 2021;9(3):289. doi: 10.3390/biomedicines9030289
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang X, Xian S, et al. CD44v6 may influence ovarian cancer cell invasion and migration by regulating the NF‑κB pathway. Oncol Lett. 2019. doi: 10.3892/ol.2019.10306
   Google Scholar
• Khan F, Gurung S, Gunassekaran GR, et al. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice. Theranostics. 2021;11(3):1326–1344. doi: 10.7150/thno.50564
   PubMed Web of Science ®Google Scholar
• Pereira C, Ferreira D, Mendes N, et al. Expression Of CD44v6-containing isoforms influences cisplatin response in gastric cancer cells. Cancers. 2020;12(4):858. doi: 10.3390/cancers12040858
   PubMed Web of Science ®Google Scholar
• Mayumi J, Habibe D, Snehalata G, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-Mediated Pathway. PLoS ONE. 2011;6(9):e24217. doi: 10.1371/journal.pone.0024217
   PubMed Web of Science ®Google Scholar
• Ni J, Cheung BB, Beretov J, et al. CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. Exp Cell Res. 2020;388(2):111850. doi: 10.1016/j.yexcr.2020.111850.
   PubMed Web of Science ®Google Scholar
• Ma L, Dong L, Chang P. CD44v6 engages in colorectal cancer progression. Cell Death Dis. 2019;10(1). doi: 10.1038/s41419-018-1265-7
   Google Scholar
• Misra S, Ghatak S, Toole BP. Regulation of MDR1 Expression and Drug Resistance by a Positive Feedback Loop Involving Hyaluronan, Phosphoinositide 3-Kinase, and ErbB2. J Biol Chem. 2005;280(21):20310–20315. doi: 10.1074/jbc.M500737200
   PubMed Web of Science ®Google Scholar
• Pereira C, Ferreira D, Lemos C, et al. CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients. bioRxiv. 2018. doi: 10.1101/468934
   Google Scholar
• Loureno BN, Springer N, Ferreira D, et al. CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell mediated ECM remodeling. Integr Biol (Camb). 2018;10(3):145. doi: 10.1039/c7ib00179g
   PubMed Web of Science ®Google Scholar
• Choi JS, Min AK, Lee HE, et al. Mucinous gastric carcinomas: clinicopathologic and molecular analyses. Cancer-Am Cancer Soc. 2010;115(15):3581–3590. doi: 10.1002/cncr.24422
   Google Scholar
• Lyngdoh BS, Dey B, Mishra J, et al. Autopsy and Case Reports2020. Autopsy And Case Reports. 2020;10(2). doi: 10.4322/acr.2020.163
   Google Scholar
• Ramrakhiani H, Thaker AK, Pisani A, et al. Magnifying Power: new Endoscopic Tools for the Diagnosis of Krukenberg Tumor. Digest Dis Sci. 2021;66(10):3296–3299. doi: 10.1007/s10620-020-06799-x
   PubMed Web of Science ®Google Scholar
• Krukenberg F. Ueber das Fibrosarcoma ovarii mucocellulare (carcinomatodes). Archiv für Gynäkologie. 1896;50:287–321. doi: 10.1007/BF01700650
   Google Scholar
• Reshad Salam HGSY. Rare Presentation of a Krukenberg Tumor. Journal Of Current Surgery. 2020. doi: 10.14740/jcs407
   PubMedGoogle Scholar
• Kubecek O, Laco J, Spacek J, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis. 2017;34(5):295–307. doi: 10.1007/s10585-017-9856-8
   PubMed Web of Science ®Google Scholar
• Lou G, Ying G, Ning XM, et al. Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. World J Gastroenterol. 2005;11:5032–5036. doi: 10.3748/wjg.v11.i32.5032
   PubMed Web of Science ®Google Scholar
• Zhao LH, Lin QL, Wei J, et al. CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Patho. 2015;8:692–701.
   PubMedGoogle Scholar
• Wang Z, Zhao K, Hackert T, et al. CD44/CD44v6 a Reliable Companion in CancerInitiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol. 2018;6:97. doi: 10.3389/fcell.2018.00097
   PubMed Web of Science ®Google Scholar
• Zhang D, Huang J, Li W, et al. Screening and identification of a CD44v6 specific peptide using improved phage display for gastric cancer targeting. Ann translat Med. 2020;8(1442):1442–1442. doi: 10.21037/atm-19-4781
   PubMedGoogle Scholar
• Zhao J, Gang R, Rong C, et al. Mucinous adenocarcinoma and non-mucinous adenocarcinoma: differing clinicopathological characteristics and computed tomography features in gastric cancer. Oncotarget. 2017;8:45698–45709. doi: 10.18632/oncotarget.17389
   PubMedGoogle Scholar
• Isobe T, Hashimoto K, Kizaki J, et al. Characteristics and prognosis of mucinous gastric carcinoma. Mol Clin Oncol. 2014;3:44–50. doi: 10.3892/mco.2014.447
   PubMedGoogle Scholar
• Wang JWXP, Lin JXLJ, Huang CM. Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer. J Cancer Res Clin. 2015;141:1809–1817. doi: 10.1007/s00432-015-1964-8
   PubMed Web of Science ®Google Scholar
• Afify AM, Craig S, Paulino AFG, et al. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9;312–318. 10.1016/j.anndiagpath.2005.07.004
   PubMedGoogle Scholar
• Zhang LR, Underhill CB, Chen LP. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995;55. 428–433. doi: 10.1002/1097-0142(19950115)75:2+<742:AID-CNCR2820751419>3.0
   PubMed Web of Science ®Google Scholar
• Bertrand P, Girard N, Delpech B, et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non‐invasive areas. Int J Cancer. 1992;52:1–6. doi: 10.1002/ijc.2910520102
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, et al. Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. Cancer Res. 2008;68:4311–4320. doi: 10.1158/0008-5472.CAN-08-0364
   PubMed Web of Science ®Google Scholar
• Xu YY, Guo M, Yang LQ, et al. Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance. Oncotarget. 2017;8:45848–45861. doi: 10.18632/oncotarget.17435
   PubMedGoogle Scholar
• Wang JL, Su WY, Lin YW, et al. CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: a meta-analysis. Oncotarget. 2016;8. 12866–12876. doi: 10.18632/oncotarget.14163
   Google Scholar
• Ma L, Dong L, Chang P. CD44v6 engages in colorectal cancer progression. Cell Death Dis. 10(1): PMID: 30631039; PMCID: PMC6328617:30. 2019 Jan 10. 10.1038/s41419-018-1265-7
   PubMedGoogle Scholar
• Pereira C, Ferreira D, Mendes N, et al. Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells. Cancers (Basel). 12(4): PMID: 32252293; PMCID: PMC7226224:858. 2020 Apr 2. 10.3390/cancers12040858
   PubMed Web of Science ®Google Scholar
• Lauren P. The two historical main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49. doi: 10.1111/apm.1965.64.1.31. PMID: 14320675.
   PubMedGoogle Scholar
• Heider KH, Dämmrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa.[J]. Cancer Research. 1993; 53(18):4197. doi: 10.1007/BF01517001
   Google Scholar
• da Cunha CB, Oliveira C, Wen X, et al. De Novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest. 2010 Nov;90(11):1604–1614. Epub 2010 Sep 20. PMID: 20856229. doi: 10.1038/labinvest.2010.155
   PubMed Web of Science ®Google Scholar
• Zhang HF, Hu P, Fang SQ. Understanding the role of CD44V6 in ovarian cancer. Oncol Lett. 2017 Aug;14(2):1989–1992. Epub 2017 Jun 13. PMID: 28789431; PMCID: PMC5530090. 10.3892/ol.2017.6377.
   PubMed Web of Science ®Google Scholar
• Zhou DX, Liu YX, Xue YH. Expression of CD44v6 and Its Association with Prognosis in Epithelial Ovarian Carcinomas. Patholog Res Int. 2012;2012:908206. doi: 10.1155/2012/908206. Epub 2012 Feb 23. PMID: 22482084; PMCID: PMC3317067.
   PubMedGoogle Scholar
• Lin X, Han T, Zhuo M, et al. A retrospective study of clinicopathological characteristics and prognostic factors of Krukenberg tumor with gastric origin. J Gastrointest Oncol. 2022 Jun;13(3):1022–1034. PMID: 35837152; PMCID: PMC9274061. doi: 10.21037/jgo-22-464
   PubMed Web of Science ®Google Scholar